KDM6A + STAG2
KDM6A and STAG2 co-occurrence in bladder cancer (TCGA)
DataTCGA PanCancer Atlas (2018) · Bladder cancer · 408 tumours · both altered in 19 (9.1 expected if independent)
Inconclusive. Not statistically significant once the number of tests run is taken into account.
A well-studied pair (311 papers): on the map it is known biology, a positive control rather than an overlooked discovery.
Signal (x) is the corrected significance on the map's scale. Efficacy (y) is credibility times actionability, the payoff if it is real.
These genes are altered together more often than chance would predict.
Bladder
This finding's tumour type arises in the highlighted organ.
No structure profile is curated for this gene.
A human gene in this finding. Not in the curated driver set, so no structured profile is shown.
KDM6A mutations in bladder cancer →KDM6A co-mutations by tumour type →Other findings with KDM6A →No structure profile is curated for this gene.
A human gene in this finding. Not in the curated driver set, so no structured profile is shown.
STAG2 mutations in bladder cancer →STAG2 co-mutations by tumour type →Other findings with STAG2 →Anatomical figure from the EBI Expression Atlas anatomogram, and predicted structures from the AlphaFold Protein Structure Database (both CC-BY-4.0). A model shows the protein's healthy fold; a highlighted residue marks a recurrent cancer position, not a prediction of a specific mutation's effect.
The raw 2×2 the FDR q and log₂ odds ratio above were computed from. It is the immutable evidence the score re-derives from: every number on this page traces back to these four counts.
| Gene state | STAG2 altered | STAG2 wild-type |
|---|---|---|
| KDM6A altered | 19 | 65 |
| KDM6A wild-type | 25 | 299 |
both 19 (expected 9.1 if independent) · KDM6A-only 65 · STAG2-only 25 · neither 299
Weak evidence. Below the α=0.05 reject threshold (e≥20). Unlike a single-look p, this stays valid under the engine's continuous re-testing.
Molecular-subtype certification is unresolved. Control scope was not recorded. Molecular-subtype control is unverified. The association remains visible, but does not qualify as a subtype-controlled discovery.
The two axes are variables: signal (x) and efficacy (y = credibility × actionability). A point high on both lands in the frontier (top-right). A strong signal with low credibility sits low and to the right: statistically strong, not worth pursuing.
- Permalink
- https://cybergenic.im/findings/8855f405-6e41-48c8-b1ff-a70d92bd206e
- First seen
- 18 Aug 2026
- Prediction registry
- Locked 18 Aug 2026, row hash
e7ac18b0a64aaf805efbf0201808ab47(not testable out of sample). How the registry works
@misc{cybergenic_8855f405,
author = {{Cybergenic}},
title = {{KDM6A and STAG2 co-occurrence in bladder cancer (TCGA)}},
year = {2026},
howpublished = {\url{https://cybergenic.im/findings/8855f405-6e41-48c8-b1ff-a70d92bd206e}},
note = {Research engine finding, first seen 2026-08-18; prediction locked 2026-08-18, registry row hash e7ac18b0a64aaf805efbf0201808ab47},
month = aug
}